By continuing to use the site you agree to our Privacy & Cookies policy

New ADHD drug for young people

A new drug has been approved for the treatment of attention deficit/hyperactivity disorder in children and adolescents.

Lisdexamfetamine dimesylate (Elvanse) is a single-daily dose long-acting prodrug stimulant.

It has received marketing authorisation from the Medicines and Healthcare products Regulatory Agency for the treatment of ADHD in children aged six years and over when response to previous methylphenidate treatment is considered clinically inadequate.

Have your say

You must sign in to make a comment.

Related Jobs

Sign in to see the latest jobs relevant to you!